argenx (ARGN.F) Stock Overview

A commercial-stage biopharma company, develops various therapies for the treatment of autoimmune diseases in the United States, Japan, China, the Netherlands, and internationally. More details

ARGN.F fundamental analysis
Snowflake Score
Valuation	2/6
Future Growth	5/6
Past Performance	3/6
Financial Health	5/6
Dividends	0/6

Rewards

Trading at 65% below our estimate of its fair value

Earnings are forecast to grow 22.04% per year

Earnings have grown 65.8% per year over the past 5 years

Risk Analysis

Shares are highly illiquid

ARGN.F Community Fair Values

Create Narrative

See what others think this stock is worth. Follow their fair value or set your own to get alerts.

NEW488,917 members

Join community and earn perks

Gain real feedbackFrom our editorial team, personally. Not silence.

Grow your followingReal investors. The kind who actually invest, not scroll past.

Unlock free accessFree premium subscription for consistent and quality authors.

Learn more Create Narrative

488,917 investors already sharing narratives

View all narratives

argenx SE Competitors

Price History & Performance

Summary of share price highs, lows and changes for argenx
Historical stock prices
Current Share Price	€935.38
52 Week High	€960.58
52 Week Low	€619.44
Beta	-0.022
1 Month Change	5.69%
3 Month Change	n/a
1 Year Change	70.81%
3 Year Change	143.59%
5 Year Change	193.80%
Change since IPO	9,050.36%

Recent updates

Shareholder Returns

	ARGN.F	US Biotechs	US Market
7D	0%	0.02%	0.6%
1Y	70.8%	36.1%	19.5%

Return vs Industry: ARGN.F exceeded the US Biotechs industry which returned 36.1% over the past year.

Return vs Market: ARGN.F exceeded the US Market which returned 19.5% over the past year.

Price Volatility

Is ARGN.F's price volatile compared to industry and market?
ARGN.F volatility
ARGN.F Average Weekly Movement	n/a
Biotechs Industry Average Movement	10.4%
Market Average Movement	7.3%
10% most volatile stocks in US Market	16.7%
10% least volatile stocks in US Market	3.2%

Stable Share Price: ARGN.F's share price has been volatile over the past 3 months compared to the US market.

Volatility Over Time: Insufficient data to determine ARGN.F's volatility change over the past year.

About the Company

Founded	Employees	CEO	Website
2008	1,863	Karen Massey	argenx.com

argenx SE, a commercial-stage biopharma company, develops various therapies for the treatment of autoimmune diseases in the United States, Japan, China, the Netherlands, and internationally. The company offers VYVGART for the treatment of gMG and immune thrombocytopenia (ITP), and VYVGART HYTRULO for the treatment of gMG and chronic inflammatory demyelinating polyneuropathy (CIDP). It also develops efgartigimod for the treatment of seronegative gMG, ocular myasthenia gravis (MG), primary ITP, grave’s disease, myositis, Sjögren’s disease, systemic sclerosis, and AMR; empasiprubart for MMN, delayed graft function, and CIDP; and adimanebart for congenital myasthenic syndrome and spinal muscular atrophy.

argenx SE Fundamentals Summary

How do argenx's earnings and revenue compare to its market cap?
ARGN.F fundamental statistics
Market cap	US$56.96b
Earnings (TTM)	US$1.49b
Revenue (TTM)	US$4.74b

38.3x

P/E Ratio

12.0x

P/S Ratio

Is ARGN.F overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
ARGN.F income statement (TTM)
Revenue	US$4.74b
Cost of Revenue	US$1.99b
Gross Profit	US$2.76b
Other Expenses	US$1.27b
Earnings	US$1.49b

Last Reported Earnings

Mar 31, 2026

Next Earnings Date

Jul 23, 2026

Earnings per share (EPS)	23.80
Gross Margin	58.11%
Net Profit Margin	31.40%
Debt/Equity Ratio	0.6%

How did ARGN.F perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2026/07/10 17:51
End of Day Share Price	2026/07/07 00:00
Earnings	2026/03/31
Annual Earnings	2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

argenx SE is covered by 52 analysts. 31 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution
null null	Baird
Colleen Kusy	Baird
Joel Beatty	Baird

argenx (ARGN.F) Stock Overview

Rewards

Risk Analysis

Join community and earn perks

argenx SE Competitors

Alnylam Pharmaceuticals

BeOne Medicines

Ascendis Pharma

Regeneron Pharmaceuticals

Price History & Performance

Recent News & Updates

Argenx Presents New Efgartigimod Data Showing Long-Term Sustained Patient Benefit In Myositis And Sjogren’s Disease At EULAR 2026

argenx SE Announces U.S. FDA Approval Expanding VYVGART and VYVGART Hytrulo for Use in All Adult Patients Living with gMG

argenx SE Brings Neuromuscular Leadership to AAN 2026 with New Data Supporting Broader VYVGART Use Across MG and CIDP

argenx SE Presents New Data and Pipeline Updates At 2026 AAN Annual Meeting

argenx SE, Annual General Meeting, May 06, 2026

Argenx Se Announces Positive Topline Results from Phase 3 Adapt Oculus Trial of Vyvgart in Ocular Myasthenia Gravis

Recent updates

Argenx Presents New Efgartigimod Data Showing Long-Term Sustained Patient Benefit In Myositis And Sjogren’s Disease At EULAR 2026

argenx SE Announces U.S. FDA Approval Expanding VYVGART and VYVGART Hytrulo for Use in All Adult Patients Living with gMG

argenx SE Brings Neuromuscular Leadership to AAN 2026 with New Data Supporting Broader VYVGART Use Across MG and CIDP

argenx SE Presents New Data and Pipeline Updates At 2026 AAN Annual Meeting

argenx SE, Annual General Meeting, May 06, 2026

Argenx Se Announces Positive Topline Results from Phase 3 Adapt Oculus Trial of Vyvgart in Ocular Myasthenia Gravis

argenx SE to Report Q1, 2026 Results on May 07, 2026

argenx SE Announces FDA Acceptance of Supplemental Biologics License Application with Priority Review for VYVGART in AChR-Ab Seronegative gMG

argenx SE Announces Management Changes

argenx SE Announces the Retirement of Peter Verhaeghe from the Board of Directors

argenx SE Provides Update on UplighTED Studies of Efgartigimod SC in Thyroid Eye Disease

argenx SE Announces VYVGART SC Prefilled Syringe for Self-Injection in Chronic Inflammatory Demyelinating Polyneuropathy Authorized for Sale by Health Canada

argenx SE Presents New Data At AANEM and MGFA Highlighting the Strength and Broad Benefit of VYVGART for Myasthenia Gravis Patients

argenx SE to Highlight Key Data and Breadth of Immunology Innovation at 2025 AANEM Annual Meeting and MGFA Scientific Session

argenx SE Announces Positive Topline Results from ADAPT Seron Study of VYVGART in Patients with AChR-Ab Seronegative gMG

argenx SE Advances Clinical Development of ARGX-119 in Congenital Myasthenic Syndromes

argenx SE Announces European Commission Approval of VYVGART Subcutaneous Injection for Chronic Inflammatory Demyelinating Polyneuropathy

argenx SE Presents New Efgartigimod Data at EULAR 2025 Highlighting Positive Phase 2 Proof-of-Concept Results in Myositis and Sjogren's Disease

argenx SE Announces Positive CHMP Opinion for VYVGART (efgartigimod alfa) Subcutaneous Injection for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)

Argenx Se Announces FDA Approval of VYVGART Hytrulo Prefilled Syringe for Self-Injection in Generalized Myasthenia Gravis and Chronic Inflammatory Demyelinating Polyneuropathy

argenx SE Highlights VYVGART Data at AAN 2025 Setting New Standard in Sustained Efficacy and Improved Quality of Life Measures for Patients Living with gMG and CIDP

Argenx Highlights FcRn Leadership with Long-Term Data and Transformational Patient Outcomes At the American Academy of Neurology 2025 Annual Meeting

argenx SE, Annual General Meeting, May 27, 2025

argenx SE to Report Q1, 2025 Results on May 08, 2025

argenx SE Announces Approval of VYVDURA (efgartigimod alfa and hyaluronidase-qvfc) in Japan for Adults with Chronic Inflammatory Demyelinating Polyneuropathy

Argenx Se Advances Clinical Development of Efgartigimod Sc in Idiopathic Inflammatory Myopathies

Zai Lab Limited and argenx Announce Approval of VYVGART Hytrulo for Chronic Inflammatory Demyelinating Polyneuropathy in China

Argenx Announces Publication in the Lancet Neurology of Pivotal Adhere Study Data in Chronic Inflammatory Demyelinating Polyneuropathy

argenx SE to Report Fiscal Year 2024 Results on Feb 27, 2025

Zai Lab and argenx Announces Approval of Efgartigimod Alfa Injection (Subcutaneous Injection) for Generalized Myasthenia Gravis in China

argenx SE Announces FDA Approval of VYVGART Hytrulo for Chronic Inflammatory Demyelinating Polyneuropathy

argenx SE Appoints Dr. Brian L. Kotzin as Non-Executive Director to the Board of Directors

argenx SE Announces Data from its Phase 3 ADHERE Trial Evaluating VYVGART Hytrulo in Patients with Chronic Inflammatory Demyelinating Polyneuropathy

argenx Se Advances Clinical Development of Efgartigimod in Primary Sjogren's Disease

Argenx SE Announces Approval of Vyvgart (Efgartigimod Alfa) in Japan for Adults with Primary Immune Thrombocytopenia

argenx SE Announces FDA Acceptance of Supplemental Biologics License Application with Priority Review for VYVGART Hytrulo in Chronic Inflammatory Demyelinating Polyneuropathy

argenx SE Announces Approval of VYVDURA (efgartigimod Alfa and Hyaluronidase-qvfc) Injection for Subcutaneous Use in Japan for Generalized Myasthenia Gravis

argenx SE, Annual General Meeting, May 07, 2024

argenx SE Reports Topline Results from ADDRESS Study of Efgartigimod SC in Pemphigus

argenx SE Reports Topline Results from ADVANCE-SC Study of VYVGART Hytrulo in Primary Immune Thrombocytopenia

argenx SE Announces European Commission Approval of Subcutaneous VYVGART (efgartigimod alfa) for Generalized Myasthenia Gravis

Argenx Se Announces 20 Presentations of Clinical Trial and Real-World Data from Studies of Vyvgart® and Vyvgart Hytrulo® (Vyvgart) in Neuromuscular Autoimmune Disease

Argenx Announces VYVGART (Efgartigimod Alfa) Authorized for Sale by Health Canada for Generalized Myasthenia Gravis

argenx SE to Report Fiscal Year 2023 Results on Feb 29, 2024

Zai Lab and argenx Report Positive Topline Data from ADHERE Study of VYVGART Hytrulo in Patients with Chronic Inflammatory Demyelinating Polyneuropathy

Zai Lab Limited and argenx Announce Approval of VYVGART (efgartigimod alfa injection) for Generalized Myasthenia Gravis in China

argenx SE Announces U.S. Food and Drug Administration Approval of VYVGART Hytrulo Injection for Subcutaneous Use in Generalized Myasthenia Gravis

argenx SE Receives Notification of PDUFA Date Extension for SC Efgartigimod

argenx SE Announces Werner Lanthaler Will Resign as Non-Executive Director of Board and Chair of Audit and Compliance Committee

argenx SE to Report Q3, 2023 Results on Oct 27, 2023

argenx SE Announces “GO” Decision in ADHERE Trial of Efgartigimod in Chronic Inflammatory Demyelinating Polyneuropathy Following Interim Analysis

argenx Announcea Interim Data from the Phase 2 Culminate Trial of cusatuzumab in Development with Cilag GmbH International

argenx SE and Zai Lab Limited Announce an Exclusive License Agreement for the Development and Commercialization of efgartigimod in Greater China, Including Mainland China, Hong Kong, Taiwan and Macau

argenx Premieres A Mystery to Me, a Docuseries Inspired by the Myasthenia Gravis Patient Experience

argenx Presents Additional Efgartigimod Data from Global Phase 3 ADAPT Trial at the Myasthenia Gravis Foundation of America 2020 Scientific Session